Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 83Thoracic 49Genitourinary 34Head & Neck 26Dermatologic 20Breast 15Other solid neoplasm 14Gynecologic 12Tumor-Agnostic 3Sarcoma 3Lymphoid 3Endocrine 3Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1NET 1CNS 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Urinary Bladder Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Prostatic Neoplasms 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Kidney Neoplasms 1Carcinoma, Merkel Cell 1Breast Neoplasms 1

Interventions

Rituximab 1401Cyclophosphamide 1305Vincristine 668Doxorubicin 587Etoposide 527Prednisone 510Cytarabine 486fludarabine 469Methotrexate 445Dexamethasone 413fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 282Radiotherapy 267venetoclax 260ibrutinib 258obinutuzumab 235Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 162Magnetic Resonance Spectroscopy 155Calcium Dobesilate 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
tremelimumab × Lymphoid × Clear all
NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

Phase 1/2 Completed
58 enrolled 24 charts
BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT02549651 2019-02-27

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

MedImmune LLC

Phase 1 Completed
32 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02205333 2017-06-28

MEDI6469

MedImmune LLC

Phase 1/2 Terminated
48 enrolled 28 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡